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Introduction
Strains of lactic acid bacteria (LAB) are commonly used
in fermentation processes, in food preservation and in
dried form as probiotic pills for human and animal
consumption. Probiotics are defined as live microbial
food supplements with beneficial effects on human
health (Salminen et al. 1998). Major groups of com-
pounds produced by LAB to which inhibitory properties
are attributed include lactic and volatile acids, hydrogen
peroxide and other antibiotic-like compounds (Gibbs
1987). Bacteriocins are antimicrobial peptides synthesized
by ribosomes of bacteria which have the property of
inhibiting other bacteria, either of the same species
(narrow spectrum) or across genera (Cotter et al. 2005).
Among the bacteriocins isolated from LAB, a distinc-
tion can be made between the following: first, class I lan-
tibiotics or small heat-stable lanthionine-containing
single- and two-peptide bacteriocins; second, class II
peptide bacteriocins or small heat-stable nonlanthionine-
containing bacteriocins; lastly, bacteriolysins or large
heat-labile proteins.
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Aims: This study focuses on the isolation and characterization of a peptide
with bacteriocin-like properties isolated from Lactobacillus rhamnosus strain 68,
previously identified by 16S rRNA gene sequencing and originating from
human gastrointestinal flora.
Methods and Results: The peptide was isolated from a supernatant of bacteria
maintained under restrictive conditions by a combination of ethanol precipita-
tion and reversed-phase chromatography. The molecular mass of the peptide as
assessed by mass spectrometry was 6433Æ8 Da. An isoelectric point of 9Æ8 was
determined by 2D-PAGE. The peptide designated rhamnosin A inhibited
Micrococcus lysodeikticus ATCC 4698 but did not inhibit Lactobacillus planta-
rum 8014 or Lact. plantarum 39268. Inhibitory activity against M. lysodeikticus
at concentrations used in this study was shown to be bacteriostatic rather than
bacteriolytic or bactericidal. Rhamnosin A retained biological activity after heat
treatment (95C, 30 min) but was sensitive to proteolytic activity of pepsin
and trypsin.
Conclusions: The N-terminal sequence of rhamnosin A, as determined by
Edman degradation and in more detail by blast analysis, did not show identity
with any currently available Lact. rhamnosus HN001-translated protein
sequences, nor any significant similarity with other sequences in the nonredun-
dant protein sequence database. Being a small, heat-stable, nonlanthionine-
containing peptide, rhamnosin A should be categorized as a class II bacteriocin.
Significance and Impact of the Study: This study describes a partial bacteriocin
sequence isolated from Lact. rhamnosus 68 and broadens our understanding of
bacteriocins.
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Class II includes pediocin-like or Listeria-active bacte-
riocins (subclass IIa), two-peptide bacteriocins (subclass
IIb), circular bacteriocins (subclass IIc) and nonpediocin
single linear peptides (subclass IId) (Cotter et al. 2005).
Bacteriocin production is often associated with probiotic
strains (Ghosh et al. 2004). The increased interest in LAB
bacteriocins stems from their potential to modify and
control the microbial ecosystems of foodstuffs. The first
bacteriocin to appear on both the European food additive
list and the United States FDA list was nisin, it was
intended for use in the production of pasteurized pro-
cessed cheese (Federal Register 1988).
Besides their applications in the food industry and their
relevance in the improvement of food quality and safety,
the increased interest in bacteriocinogenic LAB strains has
been ascribed to their potential to modulate the immune
system.
It has been suggested that some as yet unidentified
molecules from probiotic LAB can cross the epithelial
layer and inhibit the lipopolysaccharide-induced secre-
tion of tumour necrosis factor-a by monocytic action
(Kaiserlian et al. 2005). In vivo studies have
documented the ability of probiotics to modulate T
cell-mediated allergic responses (Kaiserlian et al. 2005).
The production of bacteriocin by Lactobacillus salivarius
UCC118 in vivo has been shown to afford mice protec-
tion against infection with the invasive foodborne
pathogen Listeria monocytogenes (Corr et al. 2007).
Lactobacilli are found in normal gastrointestinal and
genitourinary flora (Aguirre and Collins 1993). The
existence of the species Lactobacillus rhamnosus has
been reported in habitats as varied as sucuk (Çon and
Gökalp 2000), boza (Todorov and Dicks 2004) and in
healthy vaginal microflora (Aroutcheva et al. 2001).
Because of its immunomodulatory efficacy in the
prevention of infantile atopic diseases (Majamaa and
Isolauri 1997; Kalliomaki et al. 2001), one of the most
studied probiotic strains is Lact. rhamnosus GG (origi-
nally isolated from human intestinal flora). Concerns
were raised about the incidence of Lact. rhamnosus
GG-induced bacteremia in immunocompromised
patients following its use in Finland as a probiotic.
Such a causative link has now been dismissed (Salmi-
nen et al. 2002).
Although probiotic LAB have important benefits to
health, caution should be exercised when considering
their administration to immunocompromised subjects
(Avlami et al. 2001; Land et al. 2005; Z’Graggen et al.
2005; Brahimi et al. 2008; Tommasi et al. 2008).
The Lact. rhamnosus 68 used in this study was isolated
from human gastrointestinal flora and has been character-
ized by 16S rRNA gene sequencing and subsequent
sequence analysis (NCIMB Ltd, Aberdeen, UK; assigned
strain name NCSQ 1872). There was a sequence similarity
of 99Æ4% when compared with the Lact. rhamnosus spe-
cies, sufficient to categorize this strain as belonging to the
species Lact. rhamnosus (Janda and Abbott 2007). The
aim of this study has been to isolate and characterize a
bacteriocin produced by Lact. rhamnosus strain 68.
Materials and methods
Bacterial strains and growth conditions
Lactobacillus rhamnosus 68 and the other Lactobacillus
species used (Lactobacillus plantarum 8014 and 39268)
were grown in MRS broth (De Man et al. 1960) at 36C
without agitation. Lactobacillus rhamnosus 68 was also
kept without agitation in a chemically defined medium
(CDM) consisting of 0Æ85% sodium chloride and 0Æ5%
glucose. Micrococcus lysodeikticus ATCC 4698 was grown
in nutrient broth (NB) (Institute Torlak, Belgrade, Serbia)
at 30C with constant agitation. All bacteria were kept in
15% glycerol stock at )80C and were transferred to new
media at least three times before use.
Production and isolation of bacteriocin
MRS broth (1Æ5 l) was inoculated with one per cent
(v ⁄ v) of an overnight culture of Lact. rhamnosus 68 and
was incubated for 16 h at 37C without agitation.
Bacteria were centrifuged (1500 g, 20 min), and the
supernatant was removed. After washing with sterile
physiological solution and recentrifugation, the bacterial
pellet was transferred into the same starting volume
(1Æ5 l) of CDM. Bacterial growth was monitored by
optical density at 610 nm. After 12 h of incubation at
36C, the bacteria were centrifuged (20 000 g, 2 min) to
obtain a clear supernatant, free of cell debris. The
supernatant (1 l) was concentrated to a volume of 30 ml
by lyophilization. The concentrate was subjected to etha-
nol precipitation using one volume of the sample to
nine volumes of 96% ethanol previously cooled at
)20C. After centrifugation (1500 g, 5 min), the pellet
obtained was air-dried to remove any residual ethanol
and then dissolved in two volumes of distilled water.
Separation of bacteriocin was performed using a
reversed-phase C5 column (RPC) (Supelco, Bellefonte,
PA, USA) on an Äkta purifier (Pharmacia Amersham,
Uppsala, Sweden). Solution A consisted of distilled water
with 0Æ1% (v ⁄ v) trifluoroacetic acid (TFA). Solution B
consisted of 0Æ1% TFA (v ⁄ v) and 80% (v ⁄ v) acetonitrile
in distilled water. The column was eluted with 20
column volumes in a linear gradient of solutions A and
B. Fractions eluted from the column were dried on the
concentrator 5301 (Eppendorf system) and dissolved in
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100 ll of phosphate-buffered saline (PBS) for further
analysis. All fractions were analysed with 16% Tricine–
SDS-PAGE (Schagger and Von Jagow 1987). Protein
concentration was determined using the Lowry assay
(Lowry et al. 1951).
Biochemical characterization of bacteriocin
The isoelectric point of the peptide was assessed by
2D-PAGE according to Bollag et al. (1996). Initial separa-
tion was achieved by electrofocusing in the first dimen-
sion (5% PAGE, gradient of ampholytes pH 3Æ5–10;
Pharmacia) and there then followed a period of incuba-
tion (30 min) in the equilibration buffer [62Æ5 mmol l)1
Tris–Cl pH 6Æ8, 5% (v ⁄ v) b-mercaptoethanol, 2Æ3% SDS
(w ⁄ v) and 10% (v ⁄ v) glycerol]. The second dimension
was then run using 16% Tricine–SDS-PAGE. Gel was
stained with CBB-R250 according to Walker (2002).
Digestion of bacteriocin (2Æ5 mg) was performed over-
night using either a final concentration of 1 mg ml)1 of
pepsin (Sigma-Aldrich, St Louis, MO, USA) or trypsin
(Sigma-Aldrich) according to the method described by
Yagami et al. (2000).
Mass analysis
Mass analysis of bacteriocin was carried out using a 6210
Time-of-Flight (TOF) LC ⁄ MS system (G1969A; Agilent
Technologies, Santa Clara, CA, USA). Mobile phase was a
50 : 50 mixture of solvent A (0Æ2% formic acid in water)
and solvent B (acetonitrile) at a flow rate of
0Æ2 ml min)1. Mass spectrometer was run in positive
electron spray ionization (ESI) mode with mass ⁄ charge
(m ⁄ z) ratio in the range of 100–3200 m ⁄ z. The sample
was introduced via 1200 series HPLC system (Agilent
Technologies). Agilent MassHunter Workstation Soft-
ware was used for data acquisition, and Agilent
MassHunter Workstation Software and Analyst QS
were used for data processing.
Amino acid sequencing
Following separation by Tricine–SDS-PAGE and electro-
transfer to a PVDF membrane (Serva, Heidelberg,
Germany), the bacteriocin-containing membrane frag-
ment was washed in double-distilled water and then
stained with 0Æ1% Coomassie Blue-G (Serva) in 50%
methanol, destained in 50% methanol and air-dried.
Peptide band was excised and subjected to N-terminal
sequencing. The first 13 amino acids were determined by
Edman degradation using a Procise protein sequencer
connected to an online phenylthiohydantoin amino acid
analyser (PE Biosystems, Weiterstadt, Germany).
Biological activity assay
For the biological activity assay, M. lysodeikticus ATCC
4698 and Lact. plantarum 8014 and 39268 were used.
The procedure used was a modification of the previously
described microtitre plate assay system (Geis et al.
1983). All fractions obtained by RPC were evaporated
using Concentrator 5301 and dissolved in 0Æ1-ml PBS,
pH 7Æ2. All the test strains were grown overnight. The
cultures were diluted to 106 CFU ml)1 for the biological
activity assay, with NB for M. lysodeikticus ATCC 4698
and with MRS for Lact. plantarum 8014 and 39268. A
bacterial strain (100 ll) was incubated with different
fractions each obtained by RPC (100 ll), with solvent
controls; agitation was initiated at the appropriate
temperatures. After 16 h, samples were transferred to a
microtitre 96-well plate (Sarstedt, Germany). Optical
density at 610 nm and absorbance at 450 nm were mea-
sured with the ELISA reader (LKB Micro plate reader
5060-006; LKB, Austria). To determine thermal stability
of bacteriocin, biological activity was measured following
heat treatment at 95C (15–30 min).
Tricin-PAGE overlaying assay was then performed to
assess the inhibitory activity of the isolated bacteriocin
and the extent to which inhibition was modified by the
presence of proteolytic enzymes. The peptide
(0Æ2 mg ml)1) was digested overnight with pepsin or trip-
sin (1 mg ml)1) at 37C. The same starting amount of
bacteriocin was added to all three lanes. The gel was
washed with sterile distilled water, fixated in 70% ethanol
(10 min), then rinsed several times with sterile distilled
water (2 h) and finally washed with PBS (10 min). The
gel was further overlaid with NB supplemented with 0Æ7%
agarose and M. lysodeikticus was added to 106 CFU ml)1.
To test the effects of rhamnosin A on M. lysodeikticus
cells, a bacteriocin sample (or PBS as a control) was
added to a 1000-times diluted overnight culture of M. lyso-
deikticus cells in NB to a concentration of 0Æ1 mg ml)1.
At fixed intervals, an aliquot (1000-times diluted) was
plated onto nutrient agar and incubated (48 h) at 37C,
when clearly distinctive yellow colonies were visualized
and counted. This experiment was repeated twice, and
each time point was plated in triplicate.
Results
Isolation and biochemical characterization of the
bacteriocin
A novel bacteriocin was isolated from the medium in
which Lact. rhamnosus 68 was incubated under restrictive
conditions. The peptide was isolated by a combination of
ethanol precipitation and reversed-phase chromatography.
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Approx. 4 mg of the peptide were obtained from 1 l of
medium. Purification of the peptide was monitored by
Tricine–SDS-PAGE. Bacteriocin was eluted using RPC C5
with 35% acetonitrile. Using a 1D Tricin-PAGE, the
mobility of the isolated bacteriocin was slightly above
6Æ5 kDa (Fig. 1). Following a 2D-PAGE, the isolated
bacteriocin revealed an isoelectric point of 9Æ8. By ESI-
TOF mass spectrometry, the determined molecular mass
was 6434 Da (Fig. 2). The isolated peptide revealed the
following N-terminal sequence: AV(K)P(T)AVRKTNETLD.
Both proteolytic enzymes (trypsin and pepsin) digested the
peptide rhamnosin A after an overnight incubation at
37C (Fig. 3).
Bacteriocin activity against Micrococcus lysodeikticus
ATCC 4698
In biological assays, the peptide produced by
Lact. rhamnosus 68 showed inhibitory activity against
M. lysodeikticus ATCC 4698. Biological activity was evalu-
ated by measuring the optical density of the bacterial
growth of M. lysodeikticus (106 CFU ml)1 bacterial dilu-
tion in NB) in the presence or absence of the isolated
bacteriocin (Fig. 4). An initial rhamnosin A concentration
of 0Æ25 mg ml)1 was sufficient to inhibit the indicator
strain. Inhibition was diminished to 50% by a ten-fold







Figure 1 CBB-R250-stained Tricine–SDS-PAGE (16%) performed
under reducing conditions. Lane (1) rhamnosin A; lane (2) molecular












































Figure 2 Mass reconstruction of the active
fraction containing rhamnosin A (6210 Time-
of-Flight LC ⁄ MS). Deconvulsion was
performed with AnalystQS program, ions
selected from the interval 1100–2000 m ⁄ z.






Figure 3 CBB-R250-stained Tricine–SDS-PAGE (16%). Lane (1) pepsin
digestion of rhamnosin A after 5 min, lane (2) pepsin digestion of
rhamnosin A after 12 h, lane (3) rhamnosin A, lane (4) molecular
mass markers (6Æ5, 12Æ5, 21, 29 kDa).
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seeding the indicator bacteria (following 12 h of incuba-
tion with bacteriocin) onto plates with nutrient agar. The
number of M. lysodeikticus ATCC 4698 colonies was
considerably diminished after 12 h of incubation with
bacteriocin in comparison with the control (incubated
with PBS).
The kinetics of M. lysodeikticus CFU mean that this
diminution was not caused by bacteriolytic action. There
was no rapid decrease in CFU (Fig. 5). Heat exposure at
95C for 30 min had no influence on the biological acti-
vity of bacteriocin (Figure not shown). Exposure to pro-
teolytic enzymes diminished bacteriocin action (Fig. 6).
Discussion
Different methods have been employed for the purifica-
tion of bacteriocins produced by LAB. These are mostly
based on the ‘salting out’ of bacteriocins from the
medium by ammonium sulfate precipitation and further
separation according to charge, size or hydrophobic inter-
actions (Mortvedt et al. 1991; Parente and Riccardi 1999).
This study describes the isolation and characterization of
a novel bacteriocin from Lact. rhamnosus 68. Cultivation
conditions for rhamosin A production by Lact. rhamnosus
68 were designed to keep bacterial cells alive in starvation
conditions. The CDM was chosen for two reasons: first, it
has been noted that in certain instances bacterial growth
is not a prerequisite for bacteriocin production (ten Brink
et al. 1994; Aroutcheva et al. 2001); second, use of this
medium minimizes the risk of the preparation being con-
taminated by peptides originating from MRS. Rhamnosin
A obtained from freeze-dried CDM was purified from a
highly concentrated salt and glucose solution by ethanol
precipitation. The precipitated peptides were dissolved in
distilled water and subsequently resolved by RPC using
a C5 column. An increase in the gradient length of
reverse phase separation resulted in improved peptide
purification.
In conformity with other class II bacteriocins, rhamno-
sin A revealed a highly basic pI suggestive of a cationic
surface topography. Rhamnosin A is a heat-stable bacte-
riocin which is digestible by proteolytic enzymes present
in the gastrointestinal tract. Based on structural characteri-
stics obtained from this study (molecular mass, pI,
























Figure 4 Growth inhibition of Micrococcus lysodeikticus ATCC 4698
by rhamnosin A monitored by optical density at 610 nm. Growth
medium: (1) 50% nutrient broth (NB) in phosphate-buffered saline



















Figure 5 Effect of rhamnosin A on Micrococcus lysodeikticus cells,
measured by the number of viable cells of M. lysodeikticus per millili-
tre. ( ) Control, no rhamnosin A added and ( ) rhamnosin A added
to a concentration of 0Æ1 mg ml)1. Mean values, with standard devia-
tions, of a discrete experiment carried out in triplicate are shown.
1 2 3
Figure 6 Washed Tricin–SDS-PAGE overlaid with 106 CFU ml)1 of
Micrococcus lysodeikticus cells in nutrient broth supplemented with
0Æ7% agarose. Lane (1) rhamnosin A 0Æ2 mg ml)1, lane (2) rhamnosin
A 0Æ2 mg ml)1 pepsin digestion, lane (3) rhamnosin A 0Æ2 mg ml)1
trypsin digestion. The arrow indicates the inhibition zone.
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a class II bacteriocin. Although most bacteriocins are bac-
tericidal or bacteriolytic in nature, rhamnosin A at the
concentration used has a bacteriostatic effect. A bacterio-
static effect was previously reported for other bacteriocins
such as lactocin 27 (Upreti and Hinsdill 1975), leucono-
cin S (Lewus et al. 1992), lactacin 3147 (McAuliffe et al.
1998) and plantaricin C19 (Atrih et al. 2001). Bacteriocins
act either bactericidally or bacteriostatically. Factors,
which may affect their mode of action include dose, the
degree of purification, the growth phase of the indicator
cells and overall experimental conditions (Deraz et al.
2007). The activity of any single bacteriocin may differ
with differing bacterial strains (González et al. 1994).
Little has been published concerning Lact. rhamnosus
bacteriocins. Lactobacillus rhamnosus GG produces no
bacteriocin in MRS broth (Avonts et al. 2004). Lactobacil-
lus rhamnosus strain ST461BZ produces a bacteriocin of
2Æ8 kDa, and strain ST462BZ produces a bacteriocin of
approx. 8 kDa in MRS broth with a broad range of acti-
vity (Todorov and Dicks 2004). Lactobacillus rhamnosus
160 produces a bacteriocin with a molecular mass of
around 3Æ8 kDa with an inhibitory activity towards Micro-
coccus luteus ATCC 10420 (Li et al. 2005). Our search (8
August 2009) for bacteriocins among translated sequences
from Lact. rhamnosus HN001 at URL http://www.ncbi.
nlm.nih.gov/sites/entrez?db=protein returned several
results. One such was the predicted sequence of an
ABC-type bacteriocin ⁄ lantibiotic exporter, containing an
N-terminal double-glycine peptidase domain (accession
number EDY98323). This data suggests that the bacterio-
cin produced by Lact. rhamnosus HN001 is of the class
IIa pediocin type.
Another sequence found among the search results
returned was designated as a prebacteriocin (accession
number ZP_03212312). Scanning of this sequence for
conserved motifs as described at http://pfam.sanger.ac.uk
suggested that its N-terminal region belongs to the
Enterocin A immunity family [EntA_Immun (PF08951)].
This is another indication that Lact. rhamnosus HN001
may contain a pediocin-like molecule whose presence is
as yet unelucidated; no significant similarity with pediocin
PA-1 has been observed within the currently available
translated sequences. Because only thirteen N-terminal
amino acids have been identified, no sequence similarities
could be determined; further subclassification must there-
fore rely upon a process of elimination. Rhamnosin A
does have a specific biological activity as a single- and not
a two-peptide bacteriocin; amino acid sequencing of its
amino terminus suggests that it is not a class IIc circular
bacteriocin; for these two reasons, we believe that
Rhamnosin A is a class IId bacteriocin of the type
recently proposed and described. Categorizing rhamnosin
A as a class IId bacteriocin and simultaneously postulat-
ing that Lact. rhamnosus HN001 contains a pediocin-like
bacteriocin is clearly paradoxical. However, such
paradoxes are not uncommon as shown by the fact that
different strains of Enterococcus faecium produce bacterioc-
ins of different class II subclasses (Franz and Holzapfel
2004). We note that bacteriocin production varies both
among different strains of the same bacterial species and
in different media (Todorov and Dicks 2004). We believe
that we have identified a novel bacteriocin and our future
work will focus on a more thorough characterization of
this bacteriocin, including a characterization of its inhibi-
tory spectra and its mechanisms of action. Several mecha-
nisms of bacteriocin activity are now postulated; both
modified and unmodified peptides exert activity through
interaction with the bacterial membrane. The majority of
class II bacteriocins analysed dissipate the proton motive
force of the target cell via pore formation. There is a
nascent awareness that specific membrane molecules are
targeted by these class II bacteriocins (Héchard and Sahl
2002).
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